MCID: CRV035
MIFTS: 69

Cervical Cancer

Categories: Genetic diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Cervical Cancer

MalaCards integrated aliases for Cervical Cancer:

Name: Cervical Cancer 57 38 12 76 75 37 55 43 3 15 63 73
Uterine Cervical Neoplasm 12 73
Cervical Cancer, Somatic 57 13
Cervix Cancer 12 75
Neoplasm of Uterine Cervix 12
Uterine Cervical Neoplasms 44
Tumor of the Cervix Uteri 12
Cancer, Cervical, Somatic 40
Malignant Tumor of Cervix 73
Uterine Cervical Cancer 75
Cervix Uteri Cancer 12
Cervical Neoplasm 12
Cervix Carcinoma 73
Cerca 75

Classifications:



External Ids:

OMIM 57 603956
Disease Ontology 12 DOID:4362
ICD10 33 C53 C53.9
ICD9CM 35 180 180.9
MeSH 44 D002583
NCIt 50 C2940 C9311
KEGG 37 H00030
SNOMED-CT via HPO 69 108369006 363346000

Summaries for Cervical Cancer

MedlinePlus : 43 The cervix is the lower part of the uterus, the place where a baby grows during pregnancy. Cervical cancer is caused by a virus called HPV. The virus spreads through sexual contact. Most women's bodies are able to fight HPV infection. But sometimes the virus leads to cancer. You're at higher risk if you smoke, have had many children, use birth control pills for a long time, or have HIV infection. Cervical cancer may not cause any symptoms at first. Later, you may have pelvic pain or bleeding from the vagina. It usually takes several years for normal cells in the cervix to turn into cancer cells. Your health care provider can find abnormal cells by doing a Pap test to examine cells from the cervix. You may also have an HPV test. If your results are abnormal, you may need a biopsy or other tests. By getting regular screenings, you can find and treat any problems before they turn into cancer. Treatment may include surgery, radiation therapy, chemotherapy, or a combination. The choice of treatment depends on the size of the tumor, whether the cancer has spread and whether you would like to become pregnant someday. Vaccines can protect against several types of HPV, including some that can cause cancer. NIH: National Cancer Institute

MalaCards based summary : Cervical Cancer, also known as uterine cervical neoplasm, is related to cervix carcinoma and papilloma, and has symptoms including pelvic pain An important gene associated with Cervical Cancer is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are Human papillomavirus infection and Viral carcinogenesis. The drugs Avastin and Cervarix have been mentioned in the context of this disorder. Affiliated tissues include the cervix, cervix and testes, and related phenotypes are neoplasm and abnormality of the cervical spine

Disease Ontology : 12 A female reproductive organ cancer that is located in the cervix.

CDC : 3 Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later.

UniProtKB/Swiss-Prot : 75 Cervical cancer: A malignant neoplasm of the cervix, typically originating from a dysplastic or premalignant lesion previously present at the active squamocolumnar junction. The transformation from mild dysplastic to invasive carcinoma generally occurs slowly within several years, although the rate of this process varies widely. Carcinoma in situ is particularly known to precede invasive cervical cancer in most cases. Cervical cancer is strongly associated with infection by oncogenic types of human papillomavirus.

PubMed Health : 63 About cervical cancer: Cervical cancer is the term used to describe tumors that can grow at the lower end of the womb. These tumors usually develop from abnormal cell changes at the entrance to the womb from the vagina (the opening of the cervix). Abnormal cell changes can be detected through screening and then removed. A vaccine against viruses that cause cancer (HPV vaccine) can reduce the risk of cervical cancer.The cervix (neck of the womb) is a strong, muscular tube-like structure. The very bottom end of the cervix sticks out into the vagina a little, at the opening of the cervix. The inside of the cervix is lined with a mucous membrane. Glands in the mucous membrane produce a thick liquid (cervical mucus) that acts as a barrier, preventing germs from entering the womb from the vagina.

Wikipedia : 76 Cervical cancer is a cancer arising from the cervix. It is due to the abnormal growth of cells that have... more...

Description from OMIM: 603956

Related Diseases for Cervical Cancer

Diseases in the Cervical Cancer family:

Cervical Benign Neoplasm

Diseases related to Cervical Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 290)
# Related Disease Score Top Affiliating Genes
1 cervix carcinoma 33.9 FGFR3 HOXA11-AS STAT3 TP53
2 papilloma 32.7 CCND1 FGFR3 PTEN TP53
3 squamous cell carcinoma 32.1 CCND1 FGFR3 H19 HOTAIR HRAS MALAT1
4 adenocarcinoma 32.0 CCND1 FGFR3 H19 HRAS PIK3CA PTEN
5 retinoblastoma 31.8 CCND1 HOTAIR MALAT1 MEG3 TP53
6 sarcoma 31.5 HOTAIR HRAS PIK3CA TP53
7 uterine carcinosarcoma 31.4 HRAS PIK3CA PTEN TP53
8 penile cancer 31.4 CCND1 HRAS TP53
9 oral cancer 31.3 CCND1 MIR21 TP53
10 small cell cancer of the lung 31.3 HOTAIR MALAT1 MIR21 PIK3CA PTEN TP53
11 peutz-jeghers syndrome 31.3 PTEN SMAD4 TP53
12 endometrial stromal sarcoma 31.1 CCND1 MALAT1 TP53
13 melanoma 31.1 GAS5 H19 HOTAIR MALAT1 MEG3 PTEN
14 ovarian cancer 30.8 CCND1 GAS5 H19 HOTAIR HOXA11-AS MALAT1
15 breast cancer 30.8 CCND1 GAS5 H19 HOTAIR HOXA11-AS HRAS
16 lung cancer susceptibility 3 30.7 CCND1 FGFR3 GAS5 H19 HOTAIR HRAS
17 gastric cancer 30.6 CCND1 GAS5 H19 HOTAIR HOXA11-AS MALAT1
18 prostate cancer 30.5 CCND1 GAS5 H19 HOTAIR HRAS MALAT1
19 bladder cancer 30.5 CCEPR CCND1 FGFR3 GAS5 H19 HOTAIR
20 esophageal cancer 30.5 CCND1 GAS5 H19 HOTAIR HOXA11-AS HRAS
21 lung cancer 30.4 CCND1 GAS5 H19 HOTAIR HOXA11-AS HRAS
22 colorectal cancer 30.3 CCND1 FGFR3 GAS5 H19 HOTAIR HOXA11-AS
23 hepatocellular carcinoma 30.1 CCEPR CCND1 GAS5 H19 HOTAIR HOXA11-AS
24 primitive neuroectodermal tumor of the cervix uteri 12.4
25 malignant germ cell tumor of the cervix uteri 12.3
26 bladder squamous cell carcinoma 11.6 FGFR3 PIK3CA PTEN TP53
27 synchronous bilateral breast carcinoma 11.5 CCND1 PTEN TP53
28 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 11.5 PIK3CA PTEN TP53
29 renal cell carcinoma, papillary, 1 11.5 FGFR3 HRAS PIK3CA PTEN TP53
30 glioblastoma multiforme 11.5 CCND1 MIR21 PIK3CA PTEN STAT3 TP53
31 ovarian clear cell carcinoma 11.5 PIK3CA PTEN TP53
32 giant cell glioblastoma 11.5 FGFR3 PTEN TP53
33 female reproductive organ cancer 11.5 CCND1 HRAS PIK3CA PTEN TP53
34 adenoid cystic carcinoma 11.5 CCND1 HRAS PIK3CA PTEN TP53
35 ethmoid sinus cancer 11.5 CCND1 HRAS PIK3CA
36 nevus, epidermal 11.5 FGFR3 HRAS PIK3CA
37 ethmoid sinus adenocarcinoma 11.5 CCND1 HRAS PIK3CA
38 esophagus adenocarcinoma 11.5 MIR21 PIK3CA SMAD4 TP53
39 transitional cell carcinoma 11.5 FGFR3 HRAS PTEN TP53
40 prostate squamous cell carcinoma 11.5 HRAS PIK3CA TP53
41 adenosquamous cell lung carcinoma 11.5 FGFR3 HRAS PIK3CA
42 estrogen-receptor positive breast cancer 11.5 CCND1 PIK3CA TP53
43 anaplastic thyroid cancer 11.5 PIK3CA PTEN TP53
44 pilocytic astrocytoma 11.5 HRAS PIK3CA PTEN TP53
45 cell type cancer 11.5 CCND1 HRAS PTEN TP53
46 skin melanoma 11.5 HRAS PIK3CA PTEN TP53
47 brain cancer 11.5 HRAS PIK3CA PTEN STAT3 TP53
48 skin squamous cell carcinoma 11.5 HRAS PIK3CA TP53
49 thyroid hurthle cell adenoma 11.5 PIK3CA PTEN
50 rare adenocarcinoma of the breast 11.5 PIK3CA TP53

Comorbidity relations with Cervical Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Hydronephrosis Intestinal Obstruction
Vaginal Cancer

Graphical network of the top 20 diseases related to Cervical Cancer:



Diseases related to Cervical Cancer

Symptoms & Phenotypes for Cervical Cancer

Clinical features from OMIM:

603956

Human phenotypes related to Cervical Cancer:

32
# Description HPO Frequency HPO Source Accession
1 neoplasm 32 HP:0002664
2 abnormality of the cervical spine 32 HP:0003319

UMLS symptoms related to Cervical Cancer:


pelvic pain

GenomeRNAi Phenotypes related to Cervical Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased sensitivity to paclitaxel GR00112-A-0 8.62 PTEN SMAD4

MGI Mouse Phenotypes related to Cervical Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.7 PTEN SMAD4 STAT3 TP53 CCND1 FGFR3
2 integument MP:0010771 9.56 SMAD4 STAT3 TP53 CCND1 FGFR3 HRAS
3 neoplasm MP:0002006 9.23 SMAD4 STAT3 TP53 CCND1 FGFR3 HRAS

Drugs & Therapeutics for Cervical Cancer

PubMedHealth treatment related to Cervical Cancer: 63

The most appropriate type of treatment will mainly depend on the size of the tumor and whether the cancer has spread. If the tumor is discovered at a very early stage, a small surgical procedure (conization) might be enough. If the tumor has already spread to the surrounding tissue, doctors usually recommend having surgery to remove the entire womb (a hysterectomy). The lymph nodes are removed in a wide area around the womb too. Radiotherapy might also be considered. Radiotherapy is still an option even if the tumor can no longer be removed through surgery. In some patients it can be combined with chemotherapy.

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Avastin 18 49 BEVACIZUMAB Genentech July 2009
2
Cervarix 18 49 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
3
Gardasil 18 49 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006

Drugs for Cervical Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 471)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
3
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2 155213-67-5 392622
4
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
5
Meperidine Approved Phase 4 57-42-1 4058
6
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
7
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
8
Nicotine Approved Phase 4,Phase 1,Phase 2,Not Applicable 54-11-5 942 89594
9
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
10
Nevirapine Approved Phase 4 129618-40-2 4463
11
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 21645-51-2
12
Iron Approved Phase 4,Phase 1,Phase 2 7439-89-6 23925
13
Bethanechol Approved Phase 4 674-38-4 2370
14
Peppermint Approved, Nutraceutical Phase 4
15
Vitamin C Approved, Nutraceutical Phase 4,Phase 2 50-81-7 5785 54670067
16 Vaccines Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
17 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Epoetin alfa Phase 4,Phase 3 113427-24-0
19 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
20 Adjuvants, Anesthesia Phase 4,Phase 3,Not Applicable
21 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Analgesics, Opioid Phase 4,Phase 3,Not Applicable
23 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
24 Anesthetics, General Phase 4,Phase 3,Not Applicable
25 Anesthetics, Intravenous Phase 4,Phase 3,Not Applicable
26 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
27 Narcotics Phase 4,Phase 3,Not Applicable,Early Phase 1
28 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Hypoglycemic Agents Phase 4,Phase 2
31 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
32 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Psychotropic Drugs Phase 4,Phase 3,Phase 2
34 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2
38 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
39
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
40 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Fluorodeoxyglucose F18 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Disinfectants Phase 4
44 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Polyhexamethylene biguanide Phase 4
46 Antidepressive Agents Phase 4,Phase 2
47 Antidepressive Agents, Second-Generation Phase 4,Phase 2
48 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
49 Dopamine Agents Phase 4,Phase 2
50 Dopamine Uptake Inhibitors Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 1301)
# Name Status NCT ID Phase Drugs
1 Comparing Health Services Interventions for the Prevention of HPV-related Cancer Unknown status NCT02837926 Phase 4
2 Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China Unknown status NCT01021904 Phase 4
3 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
4 Can Alternative Treatment Have an Impact on Cervical Dysplasia? Unknown status NCT00842738 Phase 4
5 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
6 Comparing the Rate of Insufficient Cells for Diagnosis Between Surepath® and Conventional Smear in Women After Radiation Therapy for Cervical Cancer Completed NCT01988376 Phase 4
7 Effect of HPV Vaccination on Women Aged 25 Years Completed NCT02296255 Phase 4
8 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
9 Patient Navigation in the Safety Net:CONNECTeDD Completed NCT00613275 Phase 4
10 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
11 Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls Completed NCT01173900 Phase 4
12 Alternate Dosing Schedules Study for HPV Vaccine Completed NCT00862810 Phase 4
13 Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects Completed NCT00947115 Phase 4
14 Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls Completed NCT00956553 Phase 4
15 Comparison of Meperidine and Fentanyl on Pain Scale and QOL in Brachytherapy Completed NCT02684942 Phase 4 Meperidine;Fentanyl
16 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
17 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
18 Polyhexamethylene Biguanide Increases the Regression Rate of Human Papillomavirus (HPV) Infection Completed NCT01571141 Phase 4
19 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
20 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
21 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
22 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
23 Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines Recruiting NCT03180034 Phase 4
24 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study Recruiting NCT01824537 Phase 4
25 CervIcal Cancer Screening Trial by Randomization of HPV Testing Intervention for Upcoming Screening (CITRUS Study) Active, not recruiting NCT01895517 Phase 4
26 The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) Active, not recruiting NCT02629510 Phase 4 Tachosil
27 FASTER-Tlalpan Study Active, not recruiting NCT03105856 Phase 4
28 Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India Active, not recruiting NCT00923702 Phase 4
29 Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
30 Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females Active, not recruiting NCT01031069 Phase 4
31 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Active, not recruiting NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
32 To Evaluate the Efficacy and Safety of PEG-rhG-CSF(Jinyouli®) in Reducing Neutropenia in Patients With Cervical Cancer Not yet recruiting NCT03206684 Phase 4 PEG-rhG-CSF;rhG-CSF
33 Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA Not yet recruiting NCT02910596 Phase 4 bethanechol chloride
34 Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer. Not yet recruiting NCT03423082 Phase 4 18F fluciclovine
35 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Not yet recruiting NCT03349463 Phase 4 Fluciclovine F18
36 Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities Terminated NCT00629993 Phase 4
37 A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards. Terminated NCT00730847 Phase 4
38 Cisplatin Based Chemoradiation v.s Radiotherapy for Cervical Cancer and With Clinically Defined Good Prognosis Unknown status NCT00846508 Phase 3 Cisplatin
39 Randomized Trial Between Weekly and 5 Day 3 Weekly Cisplatin for Cervical Cancer Unknown status NCT00548821 Phase 3 Cisplatin
40 Postoperative Chemoradiation v.s Radiotherapy for Lymph Node Negative Cervical Cancer Patients Unknown status NCT01756170 Phase 3 paclitaxel;cisplatin
41 Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in Defined Poor-Prognostic Cervical Cancer Unknown status NCT00842660 Phase 3 Gemzar (gemcitabine)
42 Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients Unknown status NCT01755845 Phase 3 paclitaxel;cisplatin
43 Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer Unknown status NCT01554397 Phase 2, Phase 3 Cisplatin
44 Usefulness of FDG-PET for Advanced Cervical Cancer Unknown status NCT00146458 Phase 3
45 Hydralazine Valproate for Cervical Cancer Unknown status NCT00532818 Phase 3 Hydralazine and magnesium valproate;Placebo
46 Comparing Study Between Concurrent Chemoradiation and New Combination Treatment in Cervical Cancer Patients Unknown status NCT01000415 Phase 3
47 Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical Carcinoma Unknown status NCT01405235 Phase 3 Paclitaxel;Cisplatin/Paclitaxel
48 IT-system Development for Reaching Cervix Cancer Screening Non-attenders Unknown status NCT02750124 Phase 2, Phase 3
49 Impact of Erythropoietin Administration During Definitive Cervix Cancer Radiotherapy on Treatment Outcome Unknown status NCT00348738 Phase 3 Erythropoietin
50 Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV) Unknown status NCT01095198 Phase 2, Phase 3

Search NIH Clinical Center for Cervical Cancer

Cochrane evidence based reviews: uterine cervical neoplasms

Genetic Tests for Cervical Cancer

Anatomical Context for Cervical Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Cervical Cancer:

19
The Cervix

MalaCards organs/tissues related to Cervical Cancer:

41
Cervix, Testes, Lymph Node, Breast, Endothelial, T Cells, Uterus

Publications for Cervical Cancer

Articles related to Cervical Cancer:

(show top 50) (show all 4174)
# Title Authors Year
1
Usefulness of the maximum standardized uptake value for the diagnosis and staging of patients with cervical cancer undergoing positron emission tomography/computed tomography. ( 29443749 )
2018
2
Long-term outcomes of postoperative taxane/platinum chemotherapy for early stage cervical cancer: a retrospective study. ( 29446043 )
2018
3
Long non-coding RNA HOTAIR and STAT3 synergistically regulate the cervical cancer cell migration and invasion. ( 29572071 )
2018
4
SOX17 restrains proliferation and tumor formation by down-regulating activity of the Wnt/I^-catenin signaling pathway via trans-suppressing I^-catenin in cervical cancer. ( 29970906 )
2018
5
Upregulation of Long Non-Coding RNA Small Nucleolar RNA Host Gene 12 Contributes to Cell Growth and Invasion in Cervical Cancer by Acting as a Sponge for MiR-424-5p. ( 29533945 )
2018
6
ROS-Mediated Mitochondrial Pathway is Required for <i>Manilkara Zapota</i> (L.) P. Royen Leaf Methanol Extract Inducing Apoptosis in the Modulation of Caspase Activation and EGFR/NF-<i>I_</i>B Activities of HeLa Human Cervical Cancer Cells. ( 29977314 )
2018
7
The dawn of novel STI prevention methods: modelling potential unintended effects of changes in cervical cancer screening guidelines on trichomoniasis. ( 29545472 )
2018
8
Radiation-induced leiomyosarcoma of the rectum after cervical cancer treatment. ( 29439826 )
2018
9
Cervical cancer screening among transactional female sex workers in the Dominican Republic. ( 29966506 )
2018
10
Cervical cancer screening among Lebanese women. ( 29249573 )
2018
11
Anti-Hu antibody-mediated limbic encephalitis associated with cervical cancer: A case report. ( 29607578 )
2018
12
Cytochrome P450 1A1 gene polymorphisms and cervical cancer risk: A systematic review and meta-analysis. ( 29595663 )
2018
13
Prognostic significance of residual lymph node status after definitive chemoradiotherapy in patients with node-positive cervical cancer. ( 29329882 )
2018
14
DNA methylation regulated microRNAs in human cervical cancer. ( 29077234 )
2018
15
Prevalence and determinants in cytology testing for cervical cancer screening in Spain (2006-14). ( 29444273 )
2018
16
Trichomonas vaginalis infection-associated risk of cervical cancer: A meta-analysis. ( 29980111 )
2018
17
A case of peritoneal malignant mesothelioma following radiation therapy for cervical cancer. ( 29435293 )
2018
18
Insurance status and cancer treatment mediate the association between race/ethnicity and cervical cancer survival. ( 29447263 )
2018
19
Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia. ( 29444073 )
2018
20
AJUBA increases the cisplatin resistance through hippo pathway in cervical cancer. ( 29126926 )
2018
21
Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women. ( 29235108 )
2018
22
Efficacy and safety of DoceAqualip in a patient with locally advanced cervical cancer: A case report. ( 29435291 )
2018
23
Awareness and Beliefs About Cervical Cancer, the HPV Vaccine, and Cervical Cancer Screening Among Ghanaian Women with Diverse Education Levels. ( 29974412 )
2018
24
Cervical Cancer HeLa Cell Autocrine Apoptosis Induced by Co-immobilized TNF-I+ plus IFN-I^ Biomaterials. ( 29436216 )
2018
25
The difficulties of secondary prophylaxis of cervical cancer in women suffering from paranoid schizophrenia - a case study. ( 29975365 )
2018
26
Adjuvant therapy after radical trachelectomy for stage I cervical cancer. ( 29977985 )
2018
27
Novel structural approaches concerning HPV proteins: Insight into targeted therapies for cervical cancer (Review). ( 29436691 )
2018
28
Sentinel lymphadenectomy in cervical cancer using near infrared fluorescence from indocyanine green combined with technetium-99m-nanocolloid. ( 29968916 )
2018
29
Knowledge of cervical cancer and HPV vaccine in Bangladeshi women: a population based, cross-sectional study. ( 29325530 )
2018
30
Knowledge about cervical cancer and barriers toward cervical cancer screening among HIV-positive women attending public health centers in Addis Ababa city, Ethiopia. ( 29441700 )
2018
31
Fucoxanthin and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Synergistically Promotes Apoptosis of Human Cervical Cancer Cells by Targeting PI3K/Akt/NF-I_B Signaling Pathway. ( 29291370 )
2018
32
Knowledge And Perception Of Female Nursing Students About Human Papilloma Virus (Hpv), Cervical Cancer And Attitudes Towards Hpv Vaccination. ( 29979917 )
2018
33
The association of semaphorin 5A with lymph node metastasis and adverse prognosis in cervical cancer. ( 29977159 )
2018
34
Differential effects of GLI2 and GLI3 in regulating cervical cancer malignancy in vitro and in vivo. ( 29967343 )
2018
35
Dual p16 and Ki-67 Expression in Liquid-Based Cervical Cytological Samples Compared to Pap Cytology Findings, Biopsies, and HPV Testing in Cervical Cancer Screening: A Diagnostic Accuracy Study. ( 29566392 )
2018
36
<i>Bis</i>demethoxycurcumin Suppresses Migration and Invasion of Human Cervical Cancer HeLa Cells <i>via</i> Inhibition of NF-A,B, MMP-2 and -9 Pathways. ( 29970522 )
2018
37
Investigating rectal toxicity associated dosimetric features with deformable accumulated rectal surface dose maps for cervical cancer radiotherapy. ( 29980214 )
2018
38
The distribution of human papillomavirus genotypes in cervical cancer and intraepithelial neoplasia lesions among Chinese women in Yunnan Province. ( 28697900 )
2018
39
Clinical outcomes with MRI-guided image-based brachytherapy in cervical cancer: An institutional experience. ( 29102740 )
2018
40
Identification and validation of the role of matrix metalloproteinase-1 in cervical cancer. ( 29436615 )
2018
41
Cytology and high risk HPV testing in cervical cancer screening program: Outcome of 3-year follow-up in an academic institute. ( 29048733 )
2018
42
Uptake of HPV testing and extended cervical cancer screening intervals following cytology alone and Pap/HPV cotesting in women aged 30-65A years. ( 29124542 )
2018
43
Imaging and staging of neuroendocrine cervical cancer. ( 29974177 )
2018
44
A Study on Cervical Cancer Screening Using Pap Smear Test and Clinical Correlation. ( 29963597 )
2018
45
Cyclin-dependent kinase inhibitors, roscovitine and purvalanol, induce apoptosis and autophagy related to unfolded protein response in HeLa cervical cancer cells. ( 29978381 )
2018
46
Uterine and cervical cancer with irreducible pelvic organ prolapse. ( 29852160 )
2018
47
Tripartite motif-containing protein 3 plays a role of tumor inhibitor in cervical cancer. ( 29524410 )
2018
48
MEHP promotes the proliferation of cervical cancer via GPER mediated activation of Akt. ( 29382535 )
2018
49
Prediction of outcome using pretreatment<sup>18</sup>F-FDG PET/CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy. ( 29222685 )
2018
50
Therapeutic effects of I^-elemene via attenuation of the Wnt/I^-catenin signaling pathway in cervical cancer cells. ( 29363722 )
2018

Variations for Cervical Cancer

UniProtKB/Swiss-Prot genetic disease variations for Cervical Cancer:

75
# Symbol AA change Variation ID SNP ID
1 FGFR3 p.Ser249Cys VAR_004149 rs121913483

ClinVar genetic disease variations for Cervical Cancer:

6
(show top 50) (show all 262)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
3 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
4 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh38 Chromosome 18, 51065548: 51065548
5 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
6 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
7 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
8 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
9 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh38 Chromosome 11, 533467: 533467
10 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
11 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
12 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh37 Chromosome 11, 533467: 533467
13 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh37 Chromosome 11, 533466: 533466
14 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh38 Chromosome 11, 533466: 533466
15 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
16 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
17 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
18 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
19 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
20 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
21 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
22 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
23 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
24 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
25 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
26 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
27 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
28 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
29 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
30 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
31 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
32 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
33 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh38 Chromosome 14, 104780214: 104780214
34 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh37 Chromosome 20, 57484420: 57484420
35 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh38 Chromosome 20, 58909365: 58909365
36 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421
37 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh38 Chromosome 20, 58909366: 58909366
38 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic rs121913483 GRCh37 Chromosome 4, 1803568: 1803568
39 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic rs121913483 GRCh38 Chromosome 4, 1801841: 1801841
40 CTNNB1 NM_001904.3(CTNNB1): c.95A> G (p.Asp32Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913396 GRCh37 Chromosome 3, 41266098: 41266098
41 CTNNB1 NM_001904.3(CTNNB1): c.95A> G (p.Asp32Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913396 GRCh38 Chromosome 3, 41224607: 41224607
42 CTNNB1 NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
43 CTNNB1 NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh38 Chromosome 3, 41224622: 41224622
44 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097
45 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh38 Chromosome 3, 41224606: 41224606
46 CTNNB1 NM_001904.3(CTNNB1): c.110C> T (p.Ser37Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
47 CTNNB1 NM_001904.3(CTNNB1): c.110C> T (p.Ser37Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh38 Chromosome 3, 41224622: 41224622
48 SMAD4 NM_005359.5(SMAD4): c.1081C> G (p.Arg361Gly) single nucleotide variant Likely pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
49 SMAD4 NM_005359.5(SMAD4): c.1081C> G (p.Arg361Gly) single nucleotide variant Likely pathogenic rs80338963 GRCh38 Chromosome 18, 51065548: 51065548
50 SMAD4 NM_005359.5(SMAD4): c.1082G> A (p.Arg361His) single nucleotide variant Pathogenic rs377767347 GRCh37 Chromosome 18, 48591919: 48591919

Copy number variations for Cervical Cancer from CNVD:

7 (show top 50) (show all 142)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13747 1 1 27800000 Gain EPHB2 Cervical cancer
2 16425 1 124300000 247249719 Arm Cervical cancer
3 30310 1 241700000 247249719 Gain Cervical cancer
4 31746 1 30500000 163800000 Gain AIM2 Cervical cancer
5 32175 1 34400000 39600000 Gain CDCA8 Cervical cancer
6 47124 10 89600000 98000000 Loss PTEN Cervical cancer
7 48645 11 101600000 102400000 Amplification MMP1 Cervical cancer
8 48646 11 101600000 102400000 Amplification MMP13 Cervical cancer
9 51761 11 130300000 134452384 Loss Cervical cancer
10 51791 11 130800000 135006516 Loss HNT Cervical cancer
11 51792 11 130800000 135006516 Loss OPCML Cervical cancer
12 55435 11 52900000 134452384 Loss Cervical cancer
13 57095 11 63100000 130300000 Loss INT2 Cervical cancer
14 57096 11 63100000 130300000 Loss MEN1 Cervical cancer
15 57097 6 99389300 99393387 Loss POUF3 Cervical cancer
16 57098 11 63100000 130300000 Loss TRIM29 Cervical cancer
17 59362 11 74700000 85300000 Gain Cervical cancer
18 77051 13 39500000 52200000 Loss RB Cervical cancer
19 81044 14 100400000 106368585 Gain AKT1 Cervical cancer
20 97280 16 1 40700000 Loss Cervical cancer
21 106741 17 1 11200000 Loss TP53 Cervical cancer
22 108734 17 22200000 28800000 Loss CCL2 Cervical cancer
23 109725 17 28500000 29700000 Amplification Cervical cancer
24 109738 17 28800000 35400000 Amplification ERBB2 Cervical cancer
25 111034 17 34900000 35300000 Amplification Cervical cancer
26 111283 17 35400000 54900000 Amplification ABCC3 Cervical cancer
27 112092 17 37856253 37884915 Amplification ERBB2 Cervical cancer
28 112304 17 38544772 38574202 Amplification TOP2A Cervical cancer
29 117589 17 72900000 78774742 Gain Cervical cancer
30 124103 19 1 30200000 Gain Cervical cancer
31 124104 19 1 30200000 Loss Cervical cancer
32 124177 19 1 6900000 Gain SMARCA4 Cervical cancer
33 124219 19 1 6900000 Gain Cervical cancer
34 124597 19 1156797 1179434 Deletion LKB1 Cervical Cancer
35 124598 19 1156797 1179434 Deletion LKB1 Cervical cancer
36 130163 19 47800000 57600000 Gain LIG1 Cervical cancer
37 134165 19 9500000 14500000 Gain Cervical cancer
38 140388 2 197100000 242951149 Loss CASP10 Cervical cancer
39 140389 2 197100000 242951149 Loss CFLAR Cervical cancer
40 140390 2 197100000 242951149 Loss PPP1R7 Cervical cancer
41 151917 20 27100000 28400000 Amplification AHCY Cervical cancer
42 151918 20 27100000 28400000 Amplification ASXL1 Cervical cancer
43 151919 20 27100000 28400000 Amplification C20orf20 Cervical cancer
44 151920 20 27100000 28400000 Amplification E2F1 Cervical cancer
45 151921 20 27100000 28400000 Amplification GSS Cervical cancer
46 151922 20 27100000 28400000 Amplification KIF3B Cervical cancer
47 151923 20 27100000 28400000 Amplification POFUT1 Cervical cancer
48 151924 20 27100000 28400000 Amplification TPX2 Cervical cancer
49 153446 20 37100000 41100000 Gain AIB1 Cervical cancer
50 153736 20 41100000 49200000 Amplification ADNP Cervical cancer

Expression for Cervical Cancer

Search GEO for disease gene expression data for Cervical Cancer.

Pathways for Cervical Cancer

Pathways related to Cervical Cancer according to KEGG:

37
# Name Kegg Source Accession
1 Human papillomavirus infection hsa05165
2 Viral carcinogenesis hsa05203

Pathways related to Cervical Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.99 CCND1 FGFR3 HRAS PIK3CA PTEN TP53
2
Show member pathways
12.87 CCND1 HRAS PIK3CA PTEN SMAD4 STAT3
3
Show member pathways
12.77 CCND1 HRAS PIK3CA PTEN SMAD4 TP53
4
Show member pathways
12.74 FGFR3 HRAS PIK3CA PTEN TP53
5
Show member pathways
12.73 HRAS PIK3CA PTEN STAT3 TP53
6
Show member pathways
12.71 CCND1 FGFR3 HRAS PIK3CA PTEN STAT3
7 12.64 CCND1 FGFR3 HRAS PIK3CA PTEN SMAD4
8
Show member pathways
12.55 CCND1 HRAS PIK3CA SMAD4 STAT3 TP53
9
Show member pathways
12.53 FGFR3 HRAS PIK3CA PTEN TP53
10
Show member pathways
12.51 CCND1 HRAS PIK3CA PTEN STAT3
11
Show member pathways
12.5 CCND1 HRAS PIK3CA STAT3 TP53
12 12.44 CCND1 HRAS PIK3CA SMAD4 TP53
13
Show member pathways
12.43 FGFR3 HRAS PIK3CA TP53
14
Show member pathways
12.43 CCND1 HRAS PIK3CA PTEN SMAD4 STAT3
15
Show member pathways
12.42 CCND1 HRAS PIK3CA TP53
16
Show member pathways
12.33 CCND1 HRAS PIK3CA STAT3
17 12.31 CCND1 HRAS PIK3CA STAT3 TP53
18 12.2 CCND1 SMAD4 STAT3 TP53
19
Show member pathways
12.19 HRAS PIK3CA PTEN STAT3
20
Show member pathways
12.18 FGFR3 HRAS PIK3CA STAT3
21 12.18 CCND1 HRAS PIK3CA PTEN TP53
22 12.18 CCND1 HRAS MIR21 PIK3CA STAT3 TP53
23 12.16 CCND1 PTEN SMAD4 TP53
24
Show member pathways
12.15 HRAS PIK3CA PTEN STAT3
25
Show member pathways
12.1 FGFR3 HRAS PIK3CA SMAD4 STAT3
26
Show member pathways
12.1 CCND1 HRAS PIK3CA PTEN STAT3
27 12.09 HRAS PIK3CA STAT3 TP53
28 12.09 CCND1 FGFR3 HRAS PIK3CA PTEN TP53
29 12.05 FGFR3 HRAS PIK3CA SMAD4 STAT3
30 12.03 HRAS PIK3CA PTEN TP53
31 12.02 CCND1 HRAS PIK3CA TP53
32 11.99 CCND1 HRAS PTEN TP53
33
Show member pathways
11.98 CCND1 HRAS PIK3CA PTEN TP53
34 11.96 HRAS PTEN SMAD4 TP53
35 11.89 CCND1 PIK3CA PTEN TP53
36 11.88 CCND1 PTEN SMAD4 STAT3
37
Show member pathways
11.84 HRAS PIK3CA STAT3
38 11.83 CCND1 HRAS PIK3CA SMAD4 STAT3
39 11.77 CCND1 FGFR3 HRAS TP53
40
Show member pathways
11.77 CCND1 HRAS PIK3CA PTEN SMAD4 STAT3
41 11.75 CCND1 FGFR3 HRAS MIR21 MIR214 PIK3CA
42 11.72 HRAS PIK3CA PTEN TP53
43 11.71 HRAS PIK3CA STAT3
44
Show member pathways
11.66 CCND1 PIK3CA STAT3
45 11.63 HRAS SMAD4 STAT3
46 11.59 CCND1 PIK3CA PTEN TP53
47 11.58 HRAS PIK3CA PTEN STAT3
48 11.53 CCND1 SMAD4 STAT3 TP53
49 11.49 CCND1 HRAS PIK3CA PTEN SMAD4 TP53
50 11.47 FGFR3 HRAS PIK3CA PTEN TP53

GO Terms for Cervical Cancer

Biological processes related to Cervical Cancer according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.78 FGFR3 HRAS MIR21 PTEN
2 positive regulation of gene expression GO:0010628 9.65 HRAS MIR21 PTEN STAT3 TP53
3 cell proliferation GO:0008283 9.55 HRAS PTEN SMAD4 STAT3 TP53
4 interleukin-6-mediated signaling pathway GO:0070102 9.52 SMAD4 STAT3
5 negative regulation of cardiac muscle hypertrophy GO:0010614 9.51 MIR21 SMAD4
6 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.5 MIR21 PTEN SMAD4
7 regulation of mitochondrial membrane permeability GO:0046902 9.49 STAT3 TP53
8 mitotic G1 DNA damage checkpoint GO:0031571 9.46 CCND1 TP53
9 response to leptin GO:0044321 9.43 CCND1 STAT3
10 positive regulation of cell proliferation GO:0008284 9.43 CCND1 FGFR3 HRAS MIR21 PTEN STAT3
11 cellular response to leptin stimulus GO:0044320 9.4 PTEN STAT3
12 positive regulation of metalloendopeptidase activity GO:1904685 9.37 MIR21 STAT3
13 negative regulation of cell proliferation GO:0008285 9.17 HRAS MIR21 MIR214 PTEN SMAD4 STAT3

Sources for Cervical Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....